

RECEIVED  
CENTRAL FAX CENTER

AUG 02 2005

## Patent Technology Centers

### Facsimile Transmission

To:                      Name:                                      CENTRAL FAX  
                            Company:  
                            Fax Number:                      571-273-8300  
                            Voice Phone:

From:                    Name:  
                            Official Fax Number:                      (571) 273-8300  
                            Official After Final Fax Number:                      (571) 273-8300  
                            Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

---

---

Date and time of transmission: Tuesday, August 02, 2005 4:40:40 PM  
Number of pages including this cover sheet: 12

---

USPTO  
TO: CENTRAL FAX COMPANY:  
JUL. 28. 2005 2:58PM

8/2/2005 4:41 PM PAGE 2/012 Fax Server

LVM 312 616 5700

NO. 5625 P. 1

10 | 615044

### FACSIMILE TRANSMITTAL COVER SHEET

Date: July 28, 2005

Number of pages (including this  
transmittal cover sheet): 11

Our Reference: 223505

---

To: Commissioner For Patents - Attention: Examiner Taofiq A. Solola  
P.O. Box 1450 Art Unit 1626  
Alexandria, Virginia 22313-1450

Telephone: (571) 272-0709

Facsimile: (571) 273-0709 or (571) 273-8300 (general #)

---

From: Bruce M. Gagala  
Leydig, Voit & Mayer, Ltd.  
Two Prudential Plaza - Suite 4900  
Chicago, Illinois 60601-6780


Telephone: (312) 616-5800

Facsimile: (312) 616-5700

---

Message: Dear Examiner Solola: Enclosed as we discussed are the amended claims. I believe that we had previously reached agreement with respect to claims 1, 8, 9, 17 and 19-21. We had not previously reached agreement with respect to claim 11, and claims dependent thereon. As to claim 11, we have enclosed website information showing iupac nomenclature for oxamoylation which we would like to discuss with you.

Bruce M. Gagala



---

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE AND THOSE PROPERLY ENTITLED TO ACCESS TO THE INFORMATION AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND/OR EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS TRANSMISSION IS NOT THE INTENDED OR AN AUTHORIZED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY UNAUTHORIZED DISTRIBUTION, DISSEMINATION, OR DUPLICATION OF THIS TRANSMISSION IS PROHIBITED. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE OR FACSIMILE. THANK YOU.

---